169 related articles for article (PubMed ID: 35747997)
1. Percentage genome change and chromosome 7q amplification predict sorafenib response in advanced hepatocellular carcinoma.
Yu MC; Wu TH; Lee CW; Lee YS; Lian JH; Tsai CL; Hsieh SY; Tsai CN
Biomed J; 2021 Dec; 44(6 Suppl 1):S73-S83. PubMed ID: 35747997
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib.
Oh CR; Kong SY; Im HS; Kim HJ; Kim MK; Yoon KA; Cho EH; Jang JH; Lee J; Kang J; Park SR; Ryoo BY
BMC Cancer; 2019 Apr; 19(1):292. PubMed ID: 30935424
[TBL] [Abstract][Full Text] [Related]
3. Prediction of early-stage hepatocellular carcinoma using OncoScan chromosomal copy number aberration data.
Yu MC; Lee CW; Lee YS; Lian JH; Tsai CL; Liu YP; Wu CH; Tsai CN
World J Gastroenterol; 2017 Nov; 23(44):7818-7829. PubMed ID: 29209123
[TBL] [Abstract][Full Text] [Related]
4. Early predictive value of circulating biomarkers for sorafenib in advanced hepatocellular carcinoma.
Song S; Bai M; Li X; Gong S; Yang W; Lei C; Tian H; Si M; Hao X; Guo T
Expert Rev Mol Diagn; 2022 Mar; 22(3):361-378. PubMed ID: 35234564
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Ippolito D; Querques G; Pecorelli A; Talei Franzesi C; Okolicsanyi S; Strazzabosco M; Sironi S
J Comput Assist Tomogr; 2019; 43(2):206-213. PubMed ID: 30407241
[TBL] [Abstract][Full Text] [Related]
6. Liver computed tomographic perfusion for monitoring the early therapeutic response to sorafenib in advanced hepatocellular carcinoma patients.
Shen X; Wu D; Tang M; Sun H; Ji Y; Huang C; Zeng M
J Cancer Res Ther; 2018; 14(7):1556-1562. PubMed ID: 30589038
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.
Park JG
Clin Mol Hepatol; 2015 Sep; 21(3):287-94. PubMed ID: 26527250
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
Kawaoka T; Aikata H; Murakami E; Nakahara T; Naeshiro N; Tanaka M; Honda Y; Miyaki D; Nagaoki Y; Takaki S; Hiramatsu A; Waki K; Takahashi S; Chayama K
Oncology; 2012; 83(4):192-200. PubMed ID: 22890083
[TBL] [Abstract][Full Text] [Related]
9. Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
Arizumi T; Ueshima K; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
Dig Dis; 2014; 32(6):705-10. PubMed ID: 25376287
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of Sorafenib for Extrahepatic Recurrence of Hepatocellular Carcinoma after Liver Resection].
Yokoo H; Kamiyama T; Kakisaka T; Orimo T; Wakayama K; Shimada S; Tsuruga Y; Kamachi H; Taketomi A
Gan To Kagaku Ryoho; 2015 Nov; 42(12):1497-9. PubMed ID: 26805075
[TBL] [Abstract][Full Text] [Related]
11. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
Edeline J; Boucher E; Rolland Y; Vauléon E; Pracht M; Perrin C; Le Roux C; Raoul JL
Cancer; 2012 Jan; 118(1):147-56. PubMed ID: 21713764
[TBL] [Abstract][Full Text] [Related]
12. Changes in plasma interleukin-8 and tumor necrosis factor-α levels during the early treatment period as a predictor of the response to sorafenib in patients with unresectable hepatocellular carcinoma.
Iida-Ueno A; Enomoto M; Uchida-Kobayashi S; Hagihara A; Teranishi Y; Fujii H; Morikawa H; Murakami Y; Tamori A; Thuy LTT; Kawada N
Cancer Chemother Pharmacol; 2018 Nov; 82(5):857-864. PubMed ID: 30178114
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
14. Pro-angiogenic TIE-2-expressing monocytes/TEMs as a biomarker of the effect of sorafenib in patients with advanced hepatocellular carcinoma.
Shoji H; Yoshio S; Mano Y; Doi H; Sugiyama M; Osawa Y; Kimura K; Arai T; Itokawa N; Atsukawa M; Aoki Y; Fukai M; Taketomi A; Mizokami M; Kanto T
Int J Cancer; 2017 Sep; 141(5):1011-1017. PubMed ID: 28555943
[TBL] [Abstract][Full Text] [Related]
15. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
16. Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment.
Kaibori M; Sakai K; Ishizaki M; Matsushima H; De Velasco MA; Matsui K; Iida H; Kitade H; Kwon AH; Nagano H; Wada H; Haji S; Tsukamoto T; Kanazawa A; Takeda Y; Takemura S; Kubo S; Nishio K
Oncotarget; 2016 Aug; 7(31):49091-49098. PubMed ID: 27384874
[TBL] [Abstract][Full Text] [Related]
17. Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.
Takada J; Hidaka H; Nakazawa T; Kondo M; Numata K; Tanaka K; Matsunaga K; Okuse C; Kobayashi S; Morimoto M; Ohkawa S; Koizumi W
BMC Res Notes; 2015 Oct; 8():609. PubMed ID: 26502722
[TBL] [Abstract][Full Text] [Related]
18. Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma.
Lee PC; Chen YT; Chao Y; Huo TI; Li CP; Su CW; Lee MH; Hou MC; Lee FY; Lin HC; Huang YH
Liver Int; 2018 Feb; 38(2):321-330. PubMed ID: 28736952
[TBL] [Abstract][Full Text] [Related]
19. Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib.
Sakai K; Takeda H; Nishijima N; Orito E; Joko K; Uchida Y; Izumi N; Nishio K; Osaki Y
Oncotarget; 2015 Aug; 6(25):21636-44. PubMed ID: 26046304
[TBL] [Abstract][Full Text] [Related]
20. Expression of FOXM1 and Aurora-A predicts prognosis and sorafenib efficacy in patients with hepatocellular carcinoma.
Su WL; Chuang SC; Wang YC; Chen LA; Huang JW; Chang WT; Wang SN; Lee KT; Lin CS; Kuo KK
Cancer Biomark; 2020; 28(3):341-350. PubMed ID: 32390596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
